SML2624
Dexlansoprazole
≥98% (HPLC), Proton pump inhibitor, powder
别名:
(R)-(+)-Lansoprazole, (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H14F3N3O2S
化学文摘社编号:
分子量:
369.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Dexlansoprazole, ≥98% (HPLC)
InChI
1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
InChI key
MJIHNNLFOKEZEW-RUZDIDTESA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +142 to +158°, c = 1 in chloroform-d
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Dexlansoprazole is a proton pump inhibitor. It is the active enantiomer of lansoprazole used to treat gastroesophageal reflux disease (GERD).
Proton pump inhibitor; Active enantiomer of lansoprazole to treat gastroesophageal reflux disease (GERD)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Khean Lee Goh et al.
Journal of neurogastroenterology and motility, 22(3), 355-366 (2016-03-05)
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as
Karen E Hansen et al.
Gastroenterology, 156(4), 926-934 (2018-11-18)
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持